""
SYNTHESIS- Logo
A publication  of the UC Davis Cancer Center
""
Horizontal boundary
""
""
"" ""
  N E W S
"" ""
""
"" ""
""
"" ""
""
"" ""
"" Benefactors
"" ""
"" Featured Clinical Trial
"" ""
"" Calendar of Events
"" ""
"" News
""
"" ""
"" National Cancer Institute designation extended
"" Helping hands for kids with cancer
"" Just for new patients
  Koreans out-smoke other California men
  Longest survival rate for locally advanced lung cancer
  Chemotherapy after surgery boosts lung cancer survival
  Doris Matsui announces $6.5 million grant
"" ""
"" National Cancer Survivors Day celebrated
"" Ovarian cancer: Not so silent after all?
"" Ralph deVere White to lead Society of Urologic Oncology
  Smoking linked to two-thirds of cancer deaths in African American men
  Many say no to tamoxifen for breast-cancer prevention
  Cancer researcher honored
  Christine and Helen S. Landgraf Memorial Research Fund award recipients
"" ""
  Contact
"" ""
  Subscribe
"" ""
  Past issues
Vertical Seperator Line
 
Current Issue: Fall/Winter 2003
""
  NEWS
"" ""
""
"" ""
"" ""
 
""

Many say no to tamoxifen for breast-cancer prevention

 "" PHOTO — Tamoxifin
 
Tamoxifen
"" ""

Among women at high risk for breast cancer, fewer than one in five were inclined to take the drug tamoxifen to prevent the disease, according to a study by Joy Melnikow, professor of family and community medicine. Concerns about the drug's potential side effects were the primary reason. The study appeared in the May 15, 2005 issue of Cancer, a peer-reviewed journal of the American Cancer Society.

Taking tamoxifen can reduce a woman's risk of developing breast cancer by as much as 49 percent. However, the drug also increases risks for endometrial cancer, deep venous thrombosis, pulmonary embolism, painful sexual intercourse and cataracts requiring surgery.

"Potential harmful effects become much more important in the context of reducing risk for a potential disease, in contrast to treating a disease," Melnikow said. "To have successful risk-reducing agents for healthy people, it appears we will need agents with minimal side effects."

 

""
"" ""
 
"" ""
"" ""
Vertical Seperator Line
"" "" ""
     
"" "" Vertical Seperator Line "" "" "" ""
"" "" Vertical Seperator Line
""
""

UC DAVIS CANCER CENTER
4501 X Street
Sacramento, CA 95817

cancer.center@ucdmc.ucdavis.edu

© 2006 UC Regents. All rights reserved.

"" "" ""